Ollivier R, Donal E, Delaval P, Daubert J-C, Mabo P
Département de cardiologie, hôpital Pontchaillou, CHU, 2, rue Henri-Le-Guillouxn 35033 Rennes cedex 09, France.
Ann Cardiol Angeiol (Paris). 2007 Nov;56(5):231-6. doi: 10.1016/j.ancard.2006.08.002. Epub 2006 Sep 11.
The beta-blocker (BB) prescription remains insufficient despite guidelines, especially, for chronic heart failure. Patients suffering chronic obstructive pulmonary disease (COPD) are particularly less treated by BB. The level of evidence for BB prescription is however especially high and as we will focus on, the level of evidence for the safety of BB in the COPD context is convincing enough. We, thus, propose to review the existing literature in regard to this prescription of BB in the chronic heart failure, in the coronary artery disease and for high blood pressure in COPD patients. We then propose our approach to improve the level of prescription of BB in COPD patient really justifying this prescription in cardiology.
尽管有相关指南，但β受体阻滞剂（BB）的处方量仍然不足，尤其是在慢性心力衰竭方面。患有慢性阻塞性肺疾病（COPD）的患者接受BB治疗的情况尤其少。然而，BB处方的证据水平特别高，而且正如我们将关注的，BB在COPD背景下安全性的证据水平也足够有说服力。因此，我们建议回顾关于慢性心力衰竭、冠状动脉疾病以及COPD患者高血压方面BB处方的现有文献。然后，我们提出我们的方法，以提高在心脏病学中确实有理由使用BB的COPD患者的BB处方水平。
